Browse our anti-G6PC (G6PC) Antibodies

Full name:
anti-Glucose 6-Phosphatase, Catalytic Antibodies (G6PC)
On are 26 Glucose 6-Phosphatase, Catalytic (G6PC) Antibodies from 6 different suppliers available. Additionally we are shipping G6PC Kits (20) and G6PC Proteins (2) and many more products for this protein. A total of 53 G6PC products are currently listed.
AW107337, G-6-Pase, G6Pase, G6PC1, G6PT, Glc-6-Pase, GSD1, GSD1a

Most Popular Reactivities for anti-G6PC (G6PC) Antibodies

Select your species and application

anti-Mouse (Murine) G6PC Antibodies:

anti-Human G6PC Antibodies:

anti-Rat (Rattus) G6PC Antibodies:

All available anti-G6PC Antibodies

Go to our pre-filtered search.

Top referenced anti-G6PC Antibodies

  1. Mouse (Murine) Polyclonal G6PC Primary Antibody for WB - ABIN4894612 : Tao, Zhang, Zeng, Shulman, Jin: Niclosamide ethanolamine-induced mild mitochondrial uncoupling improves diabetic symptoms in mice. in Nature medicine 2014 (PubMed)
    Show all 2 references for 4894612

  2. Human Polyclonal G6PC Primary Antibody for FACS, IHC (p) - ABIN651417 : Tu, Bagnall, Duflou, Lynch, Twigg, Semsarian: Post-mortem pathologic and genetic studies in "dead in bed syndrome" cases in type 1 diabetes mellitus. in Human pathology 2010 (PubMed)
    Show all 2 references for 651417

  3. Cow (Bovine) Polyclonal G6PC Primary Antibody for IHC, WB - ABIN2781770 : Iwasa, Kobayashi, Mifuji-Moroka, Hara, Miyachi, Sugimoto, Tanaka, Fujita, Gabazza, Takei: Branched-chain amino acid supplementation reduces oxidative stress and prolongs survival in rats with advanced liver cirrhosis. in PLoS ONE 2013 (PubMed)

More Antibodies against G6PC Interaction Partners

Mouse (Murine) Glucose 6-Phosphatase, Catalytic (G6PC) interaction partners

  1. We envisage these data and models finding utility when investigating the muscle-specific functions of the 11beta-HSD1/G6PT/H6PDH triad.

  2. Data s (show NOTCH1 Antibodies)how that glucose-6-phosphatase and perilipin-5 (G6PC/PLIN5) are (show PLIN5 Antibodies)upregulated (show PLIN5 Antibodies)in notch1 knockout (KO) mice.

  3. We conclude that G6PD (show G6PD Antibodies) deficiency at the level of the animals in the present study may not be a risk factor for developing CSN-OT, but this remains to be verified for human subjects

  4. The results strongly suggested that the increase of glucagon (show GCG Antibodies) levels could account for the induction of G6pc expression in the kidneys and intestine of L-G6pc-/- mice.

  5. PPARalpha (show PPARA Antibodies) is responsible for glucose production through the up-regulation of hepatic G6Pase gene expression during fasting or type 2 diabetes animal models

  6. gene transcription in H4IIE cells mediated by hepatocyte nuclear factor-4 (show HNF4A Antibodies) alpha's stimulatory effect of peroxisome proliferator-activated receptor gamma co-activator-1 (show PPARGC1A Antibodies) alpha

  7. Evidence for the expression of the catalytic domain of hepatic glucose-6-phosphatase in pancreatic islets.

  8. Loss of G6pt activity causes neutropenia, and local production of the chemokines KC and macrophage inflammatory protein-2 (show CXCL2 Antibodies) are defective in G6pt-/- neutrophils.

  9. G6pc expression was functionally silenced by adenovirus-mediated delivery of short hairpin RNA.

  10. muscle expresses both Glc-6-Pase-beta and Glc-6-P transporter and that they can couple to form an active Glc-6-Pase complex

Human Glucose 6-Phosphatase, Catalytic (G6PC) interaction partners

  1. Notch1 (show NOTCH1 Antibodies) expression is reduced and glucose-6-phosphatase and perilipin-5 (show PLIN5 Antibodies) (G6PC/PLIN5 (show PLIN5 Antibodies)) are upregulated in liver biopsies from nonalcoholic steatohepatitis (NASH (show SAMSN1 Antibodies)) and nonalcoholic fatty liver disease (NAFLD (show TSC2 Antibodies)) patients.

  2. Mutation analysis of the G6PC gene revealed that GSD Ia accounted for 11% in GSD patients with involvement of liver. Three patients were homozygous for R83C mutation. In addition, a novel stop mutation, Y85X, was identified in a patient with the typical features of GSD Ia.

  3. Post-translational regulation of the glucose-6-phosphatase complex by cyclic AMP (show APRT Antibodies) is a crucial determinant of endogenous glucose production and is controlled by the glucose-6-phosphate transporter (show SLC37A4 Antibodies).

  4. ApoA-IV (show APOA4 Antibodies) colocalizes with NR4A1 (show NR4A1 Antibodies), which suppresses G6Pase and PEPCK (show PEPCK Antibodies) gene expression at the transcriptional level, reducing hepatic glucose output and lowering blood glucose.

  5. By direct DNA sequencing, three novel G6PC variations were identified which expanded the G6PC mutation spectrum, and provided conclusive genetic evidences for the definitive diagnosis of the Chinese patients.

  6. This study is the first to demonstrate a functional relationship between the critical gluconeogenic and glycogenolytic enzyme G6PC with the metabolic adaptations during glioblastoma invasion.

  7. The spectrum of mutations in the G6PC gene.

  8. Lipopolysaccharide and monophosphoryl lipid A also up-regulated G6PC and PCK1 (show PCK1 Antibodies) transcript abundance in a TLR4 (show TLR4 Antibodies)-dependent manner.

  9. LSD1 (show KDM1A Antibodies) regulates transcription activation of two gluconeogenic genes, FBP1 (show FBP1 Antibodies) and G6Pase.

  10. Both GSD-1a and G6PT strongly colocalised in perinuclear membranes. showed that GSD1 mutations did neither alter the G6PC or G6PT chimera localisation, nor the interaction between G6PT termini.

G6PC Antigen Profile

Antigen Summary

Glucose-6-phosphatase (G6Pase) is a multi-subunit integral membrane protein of the endoplasmic reticulum that is composed of a catalytic subunit and transporters for G6P, inorganic phosphate, and glucose. This gene (G6PC) is one of the three glucose-6-phosphatase catalytic-subunit-encoding genes in human: G6PC, G6PC2 and G6PC3. Glucose-6-phosphatase catalyzes the hydrolysis of D-glucose 6-phosphate to D-glucose and orthophosphate and is a key enzyme in glucose homeostasis, functioning in gluconeogenesis and glycogenolysis. Mutations in this gene cause glycogen storage disease type I (GSD1). This disease, also known as von Gierke disease, is a metabolic disorder characterized by severe hypoglycemia associated with the accumulation of glycogen and fat in the liver and kidneys.

Alternative names and synonyms associated with G6PC

  • glucose-6-phosphatase, catalytic (G6pc) antibody
  • glucose-6-phosphatase, catalytic subunit (G6PC) antibody
  • glucose-6-phosphatase, catalytic subunit (G6pc) antibody
  • AW107337 antibody
  • G-6-Pase antibody
  • G6Pase antibody
  • G6PC1 antibody
  • G6PT antibody
  • Glc-6-Pase antibody
  • GSD1 antibody
  • GSD1a antibody

Protein level used designations for G6PC

G-6-Pase , Glc-6-Pase-alpha , glucose-6-phosphatase , G6Pase , G6Pase-alpha , glucose-6-phosphatase alpha , glucose-6-phosphatase, catalytic (glycogen storage disease type I, von Gierke disease) , glucose-6-phosphatase catalytic subunit

14377 Mus musculus
2538 Homo sapiens
403492 Canis lupus familiaris
100134959 Sus scrofa
538710 Bos taurus
25634 Rattus norvegicus
723970 Felis catus
Selected quality suppliers for anti-G6PC (G6PC) Antibodies
Did you look for something else?